AQST: Anaphylm's rapid, user-friendly delivery and strong clinical profile position it for major market impact
Anaphylm, a sublingual film for severe allergic reactions, is poised for FDA resubmission with improved packaging and strong clinical data showing rapid onset and robust efficacy. The company is launch-ready with secured financing, a targeted commercial strategy, and a focus on payer engagement to…